Kalaris Therapeutics (KLRS) Misses Q3 EPS by 64c
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q3 EPS of ($0.64).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance
- SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
